MLYSMineralys Therapeutics Inc

Key PointsThe Chief Medical Officer of Mineralys Therapeutics reported selling 14,474 Common Stock shares across multiple transactions on June 15 and June 17, 2026, for a total value of approximately $350,000...

Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rat...

Mineralys Therapeutics (NASDAQ:MLYS) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-mineralys-therapeutics-inc-stock...

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 8.2% - Should You Buy...

Jennison Associates LLC grew its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 234.4% in the fourth quarter, according to its most recent filing with the...

Pictet Asset Management Holding SA trimmed its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 8.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 852,883 shares of the...

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's What Happened...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the business's stock in a transaction that occurred on Friday, April 17th. The shares were...